Please assess the completion status of the following clinical trial:

Trial Title: Effect of Zonisamide on Cocaine Reinforcement, Craving, and Relapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at least 21 years old, not older than 45 years.~* Evidence of cocaine dependence.~* Not seeking treatment for cocaine abuse.~* Able and willing to be restricted to our unit for 6-7 weeks.~* Able to answer frequent questionnaires reliably and consistently.~* Smoker.~Exclusion Criteria:~* Allergy to Sulfonamide drugs (e.g. topiramate, zonisamide, sulfamethoxazole/trimethoprim).~* Diabetes, respiratory insufficiency, renal tubular acidosis or renal insufficiency, heart failure, liver insufficiency, chronic diarrhea, other chronic diseases predisposing to acidosis.~* Renal insufficiency defined as serum creatine \> 1.30 mg/DL for males or \> 1.03 mg/DL for females.~* History of nephrolithiasis, unexplained hematuria on screening urinalysis.~* History of head injury (with loss of consciousness longer than a few minutes).~* History of seizure, or use of antiepileptic medications.~* HIV positive individuals who meet AIDS by Centers for Disease Control (CDC) criteria or are on antiretroviral medications.~* BMI \< 19 or BMI \> 34.~* Total cholesterol \> 240mg%.~* Serous psychiatric illness with psychosis, dementia.~* Glaucoma, family history of glaucoma, one-sided blindness.~* For female participants: being pregnant, lactating or not using an effective method of contraception.~* Physical dependence on any drug other than cocaine, nicotine, or caffeine.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Zonisamide (Type: EXPERIMENTAL): Participants administered blind capsules containing either placebo or zonisamide.
- Placebo (Type: PLACEBO_COMPARATOR): Participants administered only placebo capsules containing lactose.

Based on this trial design, predict the completion outcome and termination type (if applicable).